Cargando…

Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization

Remote ischemic preconditioning (RIPC) by repeated brief cycles of limb ischemia/reperfusion may reduce myocardial ischemia/reperfusion injury and improve patients‘ prognosis after elective coronary artery bypass graft (CABG) surgery. The signal transducer and activator of transcription (STAT)5 acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Gedik, Nilgün, Kottenberg, Eva, Thielmann, Matthias, Frey, Ulrich H., Jakob, Heinz, Peters, Jürgen, Heusch, Gerd, Kleinbongard, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627278/
https://www.ncbi.nlm.nih.gov/pubmed/28978919
http://dx.doi.org/10.1038/s41598-017-12833-2
_version_ 1783268686553939968
author Gedik, Nilgün
Kottenberg, Eva
Thielmann, Matthias
Frey, Ulrich H.
Jakob, Heinz
Peters, Jürgen
Heusch, Gerd
Kleinbongard, Petra
author_facet Gedik, Nilgün
Kottenberg, Eva
Thielmann, Matthias
Frey, Ulrich H.
Jakob, Heinz
Peters, Jürgen
Heusch, Gerd
Kleinbongard, Petra
author_sort Gedik, Nilgün
collection PubMed
description Remote ischemic preconditioning (RIPC) by repeated brief cycles of limb ischemia/reperfusion may reduce myocardial ischemia/reperfusion injury and improve patients‘ prognosis after elective coronary artery bypass graft (CABG) surgery. The signal transducer and activator of transcription (STAT)5 activation in left ventricular myocardium is associated with RIPC´s cardioprotection. Cytokines and growth hormones typically activate STATs and could therefore act as humoral transfer factors of RIPC´s cardioprotection. We here determined arterial plasma concentrations of 25 different cytokines, growth hormones, and other factors which have previously been associated with cardioprotection, before (baseline)/after RIPC or placebo (n = 23/23), respectively, and before/after ischemic cardioplegic arrest in CABG patients. RIPC-induced protection was reflected by a 35% reduction of serum troponin I release. With the exception of interleukin-1α, none of the humoral factors changed in their concentrations after RIPC or placebo, respectively. Interleukin-1α, when normalized to baseline, increased after RIPC (280 ± 56%) but not with placebo (97 ± 15%). The interleukin-1α concentration remained increased until after ischemic cardioplegic arrest and was also higher than with placebo in absolute concentrations (25 ± 6 versus 16 ± 3 pg/mL). Only interleukin-1α possibly fulfills the criteria which would be expected from a substance to be released in response to RIPC and to protect the myocardium during ischemic cardioplegic arrest.
format Online
Article
Text
id pubmed-5627278
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56272782017-10-12 Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization Gedik, Nilgün Kottenberg, Eva Thielmann, Matthias Frey, Ulrich H. Jakob, Heinz Peters, Jürgen Heusch, Gerd Kleinbongard, Petra Sci Rep Article Remote ischemic preconditioning (RIPC) by repeated brief cycles of limb ischemia/reperfusion may reduce myocardial ischemia/reperfusion injury and improve patients‘ prognosis after elective coronary artery bypass graft (CABG) surgery. The signal transducer and activator of transcription (STAT)5 activation in left ventricular myocardium is associated with RIPC´s cardioprotection. Cytokines and growth hormones typically activate STATs and could therefore act as humoral transfer factors of RIPC´s cardioprotection. We here determined arterial plasma concentrations of 25 different cytokines, growth hormones, and other factors which have previously been associated with cardioprotection, before (baseline)/after RIPC or placebo (n = 23/23), respectively, and before/after ischemic cardioplegic arrest in CABG patients. RIPC-induced protection was reflected by a 35% reduction of serum troponin I release. With the exception of interleukin-1α, none of the humoral factors changed in their concentrations after RIPC or placebo, respectively. Interleukin-1α, when normalized to baseline, increased after RIPC (280 ± 56%) but not with placebo (97 ± 15%). The interleukin-1α concentration remained increased until after ischemic cardioplegic arrest and was also higher than with placebo in absolute concentrations (25 ± 6 versus 16 ± 3 pg/mL). Only interleukin-1α possibly fulfills the criteria which would be expected from a substance to be released in response to RIPC and to protect the myocardium during ischemic cardioplegic arrest. Nature Publishing Group UK 2017-10-04 /pmc/articles/PMC5627278/ /pubmed/28978919 http://dx.doi.org/10.1038/s41598-017-12833-2 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Gedik, Nilgün
Kottenberg, Eva
Thielmann, Matthias
Frey, Ulrich H.
Jakob, Heinz
Peters, Jürgen
Heusch, Gerd
Kleinbongard, Petra
Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
title Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
title_full Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
title_fullStr Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
title_full_unstemmed Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
title_short Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
title_sort potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627278/
https://www.ncbi.nlm.nih.gov/pubmed/28978919
http://dx.doi.org/10.1038/s41598-017-12833-2
work_keys_str_mv AT gediknilgun potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization
AT kottenbergeva potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization
AT thielmannmatthias potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization
AT freyulrichh potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization
AT jakobheinz potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization
AT petersjurgen potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization
AT heuschgerd potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization
AT kleinbongardpetra potentialhumoralmediatorsofremoteischemicpreconditioninginpatientsundergoingsurgicalcoronaryrevascularization